Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.41 |
| ▸ | CES1 | P23141 | 2/20 | 0.41 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.40 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.40 |
| ▸ | CDK1 | P06493 | 1/20 | 0.40 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.40 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28230958 | 0.90 | L3MBTL1 (0.41) | CDK2ALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL27888204 | 0.87 | GPR84 (0.44) | ALDH1A1 | |
| SCHEMBL1082482 | 0.82 | HCAR2 (0.50) | ALDH1A1CYP1A2MEN1KMT2AL3MBTL1 | |
| Benzene SCHEMBL27598568 | 0.81 | GPR84 (0.40) | ALDH1A1PARP1 | |
| SCHEMBL27617396 | 0.81 | PTGS1 (0.48) | ALDH1A1CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL3429001 | 0.79 | GPR84 (0.43) | ALDH1A1 | |
| SCHEMBL23415846 | 0.78 | GPR84 (0.44) | ALDH1A1 | |
| SCHEMBL23415802 | 0.78 | GPR84 (0.44) | ALDH1A1 | |
| SCHEMBL23415837 | 0.78 | GPR84 (0.44) | ALDH1A1 | |
| SCHEMBL10790346 | 0.78 | GPR84 (0.44) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220024912-A1 | COMPOUNDS FOR TREATMENT OF CANCER | Oncternal Therapeutics, Inc. (US) | 2022-01-27 | — | — | US | disclosed |
| US-11084811-B2 | Compounds for treatment of cancer | Oncternal Therapeutics, Inc. (US) | 2021-08-10 | — | — | US | disclosed |
| EP-3793549-A1 | COMPOUNDS FOR TREATMENT OF TRIPLE NEGATIVE BREAST CANCER AND OVARIAN CANCER | University of Tennessee Research Foundation (US) | 2021-03-24 | — | — | EP | disclosed |
| EP-3793548-A1 | COMPOUNDS FOR TREATMENT OF PANCREATIC CANCER | University of Tennessee Research Foundation (US) | 2021-03-24 | — | — | EP | disclosed |
| CN-112512522-A | Compounds for the treatment of triple negative breast and ovarian cancer | 田纳西大学研究基金会 | 2021-03-16 | — | — | CN | disclosed |
| CN-112437664-A | Compounds for the treatment of pancreatic cancer | 田纳西大学研究基金会 | 2021-03-02 | — | — | CN | disclosed |
| CN-105163584-B | Compounds for the treatment of cancer | 田纳西大学研究基金会 | 2019-06-04 | — | — | CN | disclosed |
| CN-109568312-A | Compound for treating cancer | 田纳西大学研究基金会 | 2019-04-05 | — | — | CN | disclosed |
| EP-2608671-B1 | COMPOUNDS FOR TREATMENT OF CANCER | GTX INC (US) | 2018-12-12 | — | — | EP | disclosed |
| US-20180325872-A1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2018-11-15 | — | — | US | disclosed |
| WO-2014138279-A1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2014-09-12 | — | — | WO | disclosed |
| US-8822513-B2 | Compounds for treatment of cancer | GTX, INC. (US) | 2014-09-02 | — | — | US | disclosed |
| WO-2012027481-A9 | COMPOUNDS FOR TREATMENT OF CANCER | GTX, INC. (US) | 2013-10-10 | — | — | WO | disclosed |
| US-20130197049-A1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2013-08-01 | — | — | US | disclosed |
| EP-2608671-A1 | COMPOUNDS FOR TREATMENT OF CANCER | Gtx, Inc. (US) | 2013-07-03 | — | — | EP | disclosed |
| EP-2542081-A1 | COMPOUNDS FOR TREATMENT OF CANCER | Gtx, Inc. (US) | 2013-01-09 | — | — | EP | disclosed |
| US-20120071524-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2012-03-22 | — | — | US | disclosed |
| WO-2012027481-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTX, INC. (US) | 2012-03-01 | — | — | WO | disclosed |
| US-20110257196-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2011-10-20 | — | — | US | disclosed |
| WO-2011109059-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTX, INC. (US) | 2011-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071524-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | CES2 3727/4885CES1 3465/4885CCNB2 860/4885 |
| US-20180325872-A1 | COMPOUNDS FOR TREATMENT OF CANCER | BRAF, NRAS, RAF1 | CES2 4836/4885CES1 4630/4885CCNB2 691/4885 |
| US-20130197049-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | CES2 3727/4885CES1 3465/4885CCNB2 860/4885 |
| US-11084811-B2 | Compounds for treatment of cancer | KLK3, BRDT, ACP3 | CES2 3727/4885CES1 3465/4885CCNB2 860/4885 |
| US-20220024912-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | CES2 3727/4885CES1 3465/4885CCNB2 860/4885 |
| US-20110257196-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | CES2 3727/4885CES1 3465/4885CCNB2 860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.